News Wire

The U.S. Preventive Services Task Force (USPSTF) has reiterated its recommendation that all women planning to or who could become pregnant should take a daily supplement containing 400 to 800 mcg of folic acid to help prevent neural tube defects.  The USPSTF issued a similar recommendation in 2009.

An experimental therapy stops aggressive, treatment-resistant, and deadly brain cancers called glioblastoma and high-grade gliomas in laboratory tests on human cells and in mouse models, researchers report in the journal Cancer Cell.

As part of its drive to slow the development of antimicrobial resistance, the FDA has revised annual reporting requirements for all antimicrobials sold or distributed for use in animals intended for human consumption or food-producing animals.

America’s biopharmaceutical research companies are currently developing more than 560 medicines for patients with rare diseases, according to a report released by the Pharmaceutical Research and Manufacturers of America (PhRMA) and the ALS Association.

Allergan and Gedeon Richter have announced positive results from Venus I, one of two pivotal phase 3 clinical trials evaluating the efficacy and safety of ulipristal acetate in women with uterine fibroids.

A pivotal clinical trial of the Tecnis Symfony one-piece acrylic intraocular lens (IOL) met its primary endpoint of improved intermediate vision, Abbott has announced.

A potential drug therapy developed at the University of Pittsburgh (Pitt) Center for Vaccine Research (CVR) has proven effective against tough bacterial biofilms and a deadly respiratory virus simultaneously. The drug outperforms traditional therapies in the laboratory setting.

It is well known that men and women differ in terms of cancer susceptibility, survival, and mortality, but exactly why this occurs at a molecular level has been poorly understood.

Children whose mothers gain excess weight or have elevated blood sugar during their pregnancies are more likely to become overweight or obese during their first decade of life, according to a new study published in Maternal and Child Health Journal.

A new study finds the use of moderate sedation, in which patients do not need a breathing tube, leads to better clinical outcomes compared to general anesthesia for patients undergoing transcatheter aortic valve replacement (TAVR).

Intarcia Therapeutics, Inc., has announced top-line results from its FREEDOM-CVO trial, which evaluated the cardiovascular (CV) safety of ITCA 650, a matchstick-size, subdermal osmotic pump that delivers exenatide for the continuous control of type-2 diabetes. The trial met its primary and secondary endpoints and succeeded in delivering the clinical results necessary for regulatory filings.

A research team from Duke Health has developed an antibody from the body’s own immune system that preferentially attacks cancer cells. The antibody works by targeting a natural defense mechanism that cancer tumors exploit.

For the first time, scientists at Albert Einstein College of Medicine have developed a technology allowing them to “see” single molecules of messenger RNA as they are translated into proteins in living mammalian cells. Initial findings using this technology that may shed light on neurological diseases as well as cancer were published online in Science.

A new FDA rule asserts the agency’s authority over all tobacco products—including e-cigarettes, cigars, hookah tobacco, and pipe tobacco—and restricts the sale of these products to minors.

A new study of more than 10,000 patients treated long-term with the blood thinner warfarin reveals higher rates of dementia for patients with atrial fibrillation (AF) versus patients without the common heart rhythm disorder.

Pages